## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 3.90 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($159.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Assessing Jazz Pharmaceuticals (JAZZ) Valuation After a Strong Year-to-Date Share Price Rally**
- Source: Simply Wall Street | 20251222T150925 | Somewhat-Bullish | Relevance: 100%
- Jazz Pharmaceuticals (JAZZ) has seen a significant share price rally of about 35% year-to-date, trading at $166.99, yet analysts believe it is still undervalued with a narrative fair value of $213. Despite potential risks from patent expiries and competition, investor momentum is building due to pipeline progress and earnings growth. The article suggests exploring the detailed narrative to understand the underlying projections and risks.

**2. 211,185 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Wedge Capital Management L L P NC**
- Source: MarketBeat | 20251221T121011 | Neutral | Relevance: 100%
- Wedge Capital Management L L P NC recently acquired a new stake of 211,185 shares in Jazz Pharmaceuticals PLC ($JAZZ), valued at approximately $27.83 million. Despite this institutional accumulation, company insiders have been net sellers, divesting over $22 million worth of shares in the last 90 days. Wall Street analysts maintain a "Moderate Buy" rating for JAZZ, with an average price target of $200.47.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Piper Sandler | $219 | $147 | +49% |
| 2025-11-24 | UBS | $188 | $163 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-11-24 | UBS | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 13 ($5.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.3M in recent transactions.
3. Valuation stretched: PEG 3.9x requires aggressive growth execution.
4. Elevated short interest (9.5%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.90 signals overvaluation risk, limited margin of safety. Forward P/E 7.5x attractive for 179% earnings growth. Analyst sentiment positive (2 raises, avg +32%). Insider selling cluster ($5.3M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.3B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.90 |
| Forward P/E | 7.5 |
| Current P/E | 20.9 |
| YoY Growth | 179.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 1.6% to -0.1% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.0pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.05), momentum weakening. RSI neutral at 58. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.05% (CS: 68) | Neutral |
| RSI_14 | 58.3 | Neutral |
| MACD Histogram | -1.05 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.097x | Above |
| vs SMA200 | 1.335x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $169.47
- **Stop Loss:** $159.93 (5.6% risk)
- **Target:** $179.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 125
- **Position Value:** $21,183.75
- **Portfolio %:** 21.18%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*